Part B Payments for 340B-Purchased Drugs (OEI-12-14-00030) (2015)

Government Record · U.S. Department of Health and Human Services, Office of Inspector General · November 2015

U.S. Department of Health, 2015-11: OIG estimated that in 2013 Medicare Part B paid 340B covered entities $1.3 billion (58%) more than the ceiling prices they paid for the same drugs. For five high-expenditure cancer drugs, covered entities retained $5,749 to $13,336 per beneficiary versus under $1,000 for non-340B providers.

covered entities spent $2.2 billion to acquire Part B drugs and were reimbursed $3.5 billion for these purchases by Medicare.

p. 8

U.S. Department of Health, 2015-11: OIG estimated that in 2013 Medicare Part B paid 340B covered entities $1.3 billion (58%) more than the ceiling prices they paid for the same drugs. For five high-expenditure cancer drugs, covered entities retained $5,749 to $13,336 per beneficiary versus under $1,000 for non-340B providers. Federal evaluation, no funder or conflicts. No product or maker. Comparator: 340B ceiling prices vs ASP-based Part B payment, and covered vs non-covered entities, 2013 claims. The 58% aggregate spread is the closest thing in the federal record to a 'margin over 50%' (cross-reference F3), but it applies only to 340B covered entities and only to the drugs reviewed. Study type: regulatory record.